Last reviewed · How we verify
Pirfenidone Capsules （400 mg）
Pirfenidone Capsules （400 mg） is a Small molecule drug developed by Beijing Continent Pharmaceutical Co, Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Pirfenidone Capsules （400 mg） |
|---|---|
| Sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia (PHASE2, PHASE3)
- Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis (PHASE1, PHASE2)
- Pirfenidone, an Antifibrotic and Antiinflammatory Drug (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pirfenidone Capsules （400 mg） CI brief — competitive landscape report
- Pirfenidone Capsules （400 mg） updates RSS · CI watch RSS
- Beijing Continent Pharmaceutical Co, Ltd. portfolio CI
Frequently asked questions about Pirfenidone Capsules （400 mg）
What is Pirfenidone Capsules （400 mg）?
Pirfenidone Capsules （400 mg） is a Small molecule drug developed by Beijing Continent Pharmaceutical Co, Ltd..
Who makes Pirfenidone Capsules （400 mg）?
Pirfenidone Capsules （400 mg） is developed by Beijing Continent Pharmaceutical Co, Ltd. (see full Beijing Continent Pharmaceutical Co, Ltd. pipeline at /company/beijing-continent-pharmaceutical-co-ltd).
What development phase is Pirfenidone Capsules （400 mg） in?
Pirfenidone Capsules （400 mg） is in Phase 2.